Medroxyprogesterone is a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. MedsAcross supplies Medroxyprogesterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.
Source: US FDA prescribing information
Secondary Amenorrhea PROVERA tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days. A dose for inducing an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen is 10 mg of PROVERA daily for 10 days. In cases of secondary amenorrhea, therapy may be started at any time. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing PROVERA therapy. Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of Organic Pathology Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of PROVERA may be given daily for 5 to 10 days.
Source: US FDA prescribing information
PROVERA is contraindicated in women with any of the following conditions: 1. Undiagnosed abnormal genital bleeding. 2. Known, suspected, or history of breast cancer. 3. Known or suspected estrogen- or progesterone-dependent neoplasia. 4. Active DVT, PE, or a history of these conditions 5. Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions. 6. Known anaphylactic reaction or angioedema to PROVERA. 7. Known liver impairment or disease. 8. Known or suspected pregnancy.
Source: US FDA prescribing information
Boxed warning (cardiovascular disorders, breast cancer and probable dementia for estrogen plus progestin therapy): Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. See BOXED WARNINGS. 1. Cardiovascular Disorders An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy. Should any of these events occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a.
Source: US FDA prescribing information
See BOXED WARNINGS, WARNINGS, and PRECAUTIONS. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reactions have been reported in women taking PROVERA tablets, without concomitant estrogens treatment: 1. Genitourinary system Abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. 2. Breasts Breast tenderness, mastodynia or galactorrhea has been reported. 3. Cardiovascular Thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. 4. Gastrointestinal Nausea, cholestatic jaundice. 5.
Source: US FDA prescribing information
Store at controlled room temperature 20° to 25°C (68° to 77°F). "Keep out of reach of children"
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
10 presentations of Medroxyprogesterone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Medroxyprogesterone 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Medroxyprogesterone 150 mg/1 mL injectable suspensionIntramuscularGeneric name | — | US FDA | Available on request |
| Medroxyprogesterone 2.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Medroxyprogesterone 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Depo-Provera 150 mg/1 mL injectable suspensionIntramuscular | Pharmacia & Upjohn | US FDA | Available on request |
| Medroxyprogesterone 150 mg/1 mL extended-release injectable suspensionIntramuscularGeneric name | — | US FDA | Available on request |
| Depo-SubQ Provera 104 mg/0.65 mL injectable suspensionSubcutaneous | Pharmacia & Upjohn | US FDA | Available on request |
| Provera 10 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Provera 2.5 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Provera 5 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
3 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 18 June 1959 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Medroxyprogesterone in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 10 presentations of Medroxyprogesterone and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Medroxyprogesterone, including Depo-Provera, Depo-SubQ Provera, Provera.
Yes. The US FDA first approved Medroxyprogesterone on 18 June 1959, according to Drugs@FDA.
No listed presentation of Medroxyprogesterone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Medroxyprogesterone is classified under ATC code G03AC06 (Medroxyprogesterone).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.